A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central ...

[63] A second trial, called Stalevo Reduction in Dyskinesia Evaluation (STRIDE-PD), was designed to evaluate whether Stalevo would delay the onset of dyskinesia compared with levodopa/carbidopa.